ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is TG Therapeutics, Inc. ?
1
With a growth in Net Profit of 457.06%, the company declared Very Positive results in Jun 25
- NET SALES(Q) Highest at USD 141.15 MM
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
- OPERATING PROFIT(Q) Highest at USD 34.9 MM
2
With ROE of 16.92%, it has a expensive valuation with a 26.81 Price to Book Value
- Over the past year, while the stock has generated a return of -4.71%, its profits have fallen by -0.1%
3
High Institutional Holdings at 80.19%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to TG Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is TG Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
TG Therapeutics, Inc.
-6.02%
2.05
52.48%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
240.08%
EBIT Growth (5y)
19.42%
EBIT to Interest (avg)
-23.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.13
Sales to Capital Employed (avg)
0.72
Tax Ratio
6.21%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
80.19%
ROCE (avg)
24.02%
ROE (avg)
8.40%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
158
Industry P/E
Price to Book Value
26.81
EV to EBIT
105.83
EV to EBITDA
105.38
EV to Capital Employed
30.60
EV to Sales
16.39
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
28.91%
ROE (Latest)
16.92%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend36What is working for the Company
NET SALES(Q)
Highest at USD 141.15 MM
INTEREST COVERAGE RATIO(Q)
The company hardly has any interest cost
OPERATING PROFIT(Q)
Highest at USD 34.9 MM
PRE-TAX PROFIT(Q)
Highest at USD 31.1 MM
NET PROFIT(Q)
Highest at USD 28.35 MM
EPS(Q)
Highest at USD 0.17
-11What is not working for the Company
INTEREST(HY)
At USD 13.47 MM has Grown at 115.05%
DEBT-EQUITY RATIO
(HY)
Highest at 0.67 %
Here's what is working for TG Therapeutics, Inc.
Pre-Tax Profit
At USD 31.1 MM has Grown at 190.72%
over average net sales of the previous four periods of USD 10.7 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 28.35 MM has Grown at 182.49%
over average net sales of the previous four periods of USD 10.04 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 141.15 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Sales
At USD 141.15 MM has Grown at 46.12%
over average net sales of the previous four periods of USD 96.6 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD 34.9 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 31.1 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 28.35 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.17
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Here's what is not working for TG Therapeutics, Inc.
Interest
At USD 13.47 MM has Grown at 115.05%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at 0.67 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
